Idexx Laboratories Stock Beta
| IX1 Stock | EUR 420.70 3.50 0.83% |
IDEXX Laboratories fundamentals help investors to digest information that contributes to IDEXX Laboratories' financial success or failures. It also enables traders to predict the movement of IDEXX Stock. The fundamental analysis module provides a way to measure IDEXX Laboratories' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to IDEXX Laboratories stock.
IDEXX |
IDEXX Laboratories Company Beta Analysis
IDEXX Laboratories' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current IDEXX Laboratories Beta | 1.17 |
Most of IDEXX Laboratories' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, IDEXX Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, IDEXX Laboratories has a Beta of 1.1747. This is 36.59% higher than that of the Healthcare sector and 18.42% lower than that of the Diagnostics & Research industry. The beta for all Germany stocks is notably lower than that of the firm.
IDEXX Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses IDEXX Laboratories' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of IDEXX Laboratories could also be used in its relative valuation, which is a method of valuing IDEXX Laboratories by comparing valuation metrics of similar companies.IDEXX Laboratories is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, IDEXX Laboratories will likely underperform.
IDEXX Fundamentals
| Return On Equity | 1.05 | |||
| Return On Asset | 0.22 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.27 % | |||
| Current Valuation | 35.12 B | |||
| Shares Outstanding | 82.9 M | |||
| Shares Owned By Insiders | 0.39 % | |||
| Shares Owned By Institutions | 92.77 % | |||
| Price To Earning | 57.45 X | |||
| Price To Book | 75.09 X | |||
| Price To Sales | 9.95 X | |||
| Revenue | 3.37 B | |||
| Gross Profit | 2 B | |||
| EBITDA | 1.01 B | |||
| Net Income | 679.09 M | |||
| Cash And Equivalents | 116.62 M | |||
| Cash Per Share | 1.36 X | |||
| Total Debt | 694.39 M | |||
| Current Ratio | 1.01 X | |||
| Book Value Per Share | 7.34 X | |||
| Cash Flow From Operations | 542.98 M | |||
| Earnings Per Share | 7.59 X | |||
| Price To Earnings To Growth | 7.23 X | |||
| Target Price | 707.0 | |||
| Number Of Employees | 10.78 K | |||
| Beta | 1.17 | |||
| Market Capitalization | 37.22 B | |||
| Total Asset | 2.75 B | |||
| Z Score | 32.8 | |||
| Net Asset | 2.75 B |
About IDEXX Laboratories Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze IDEXX Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of IDEXX Laboratories using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of IDEXX Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in IDEXX Stock
When determining whether IDEXX Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of IDEXX Laboratories' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Idexx Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Idexx Laboratories Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.